Literature DB >> 1588788

Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis.

P Fenaux1, C Preudhomme, J L Laï, I Quiquandon, P Jonveaux, M Vanrumbeke, C Sartiaux, P Morel, M H Loucheux-Lefebvre, F Bauters.   

Abstract

Mutations of exons 5 to 8 of the p53 gene were looked for in 39 cases of B-cell chronic lymphocytic leukemia (CLL) using polymerase chain reaction single-strand conformation polymorphism analysis and DNA sequencing. All patients also had cytogenetic analysis. A point mutation, leading to an amino acid change in the p53 protein was found in four cases, involving exon 7 (one case) or exon 8 (three cases). Mutations seemed to predominate in advanced clinical stages (Binet's stage C). All four patients with 17p monosomy had a mutation whereas no mutation was found in the 35 patients with cytogenetically normal 17p. These findings suggest that p53 mutations are relatively rare in B-cell CLL, and largely predominate or may even be restricted to patients with 17p monosomy (who constitute about 5% of all B-cell CLL patients in large published series). In those patients, the mutations may play a role in leukemogenesis through loss of tumor suppressive activity of normal p53 genes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588788

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

Review 1.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

3.  Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Authors:  Paolo Strati; Michael J Keating; Susan M O'Brien; Alessandra Ferrajoli; Jan Burger; Stefan Faderl; Francesco Paolo Tambaro; Nitin Jain; William G Wierda
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

4.  Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Kumudha Balakrishnan; Ramadevi Nimmanapalli; Farhad Ravandi; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

5.  Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization.

Authors:  Sunita R Setlur; Chunhwa Ihm; Joelle Tchinda; Soheil Shams; Lillian Werner; Eun Kyung Cho; Christina Thompson; Kimberly Phillips; Laura Z Rassenti; Thomas J Kipps; Donna Neuberg; Arnold S Freedman; Charles Lee; Jennifer R Brown
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

6.  Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia.

Authors:  G Gaidano; E W Newcomb; J Z Gong; V Tassi; A Neri; A Cortelezzi; R Calori; L Baldini; R Dalla-Favera
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

Review 7.  What is the best frontline therapy for patients with CLL and 17p deletion?

Authors:  Xavier C Badoux; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

8.  Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Authors:  Robert L Dilley; Weijie Poh; Douglas E Gladstone; James G Herman; Margaret M Showel; Judith E Karp; Michael A McDevitt; Keith W Pratz
Journal:  Leuk Res       Date:  2013-12-30       Impact factor: 3.156

9.  Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.

Authors:  Jennifer A Woyach; Nyla A Heerema; John Zhao; Andrew McFaddin; Amy Stark; Thomas S Lin; Leslie A Andritsos; Kristie A Blum; Joseph M Flynn; Jeffrey A Jones; John C Byrd
Journal:  Br J Haematol       Date:  2009-12-16       Impact factor: 6.998

10.  The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine.

Authors:  R B Gartenhaus; P Wang; M Hoffman; D Janson; K R Rai
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.